JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266455

Human CCNL2 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CCNL2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human CCNL2 knockout HEK-293T cell line (AB266455)
  • Sanger seq

Unknown

Sanger Sequencing - Human CCNL2 knockout HEK-293T cell line (AB266455)

Homozygous : 1 bp deletion in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266455-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266455-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266455 Human CCNL2 knockout HEK-293T cell line", "number":"AB266455-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266455-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266455-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266455 Human CCNL2 knockout HEK-293T cell line", "number":"AB266455-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266455-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266455 Human CCNL2 knockout HEK-293T cell line", "number":"AB266455-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266455-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266455 Human CCNL2 knockout HEK-293T cell line", "number":"AB266455-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CCNL2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CCNL2 also known as Cyclin L2 is a protein that plays a role in the regulation of transcription. This protein weighs approximately 59 kDa and contains conserved cyclin domains which aid in its function. It is mainly expressed in tissues like the brain liver and muscle where it performs various regulatory tasks. By interacting with certain kinases CCNL2 helps control the cell cycle's progression particularly during transitions between phases.
Biological function summary

Cyclin L2 modulates transcription processes by associating with splicing factors and RNA polymerase II. It is a part of the spliceosomal complex which influences mRNA processing by ensuring proper splicing of pre-mRNA. This regulation is important for generating diverse and functionally appropriate mRNA transcripts which influences cellular outcome and function. CCNL2's capability to bind with cdk kinases further enhances its role in managing transcription and cell cycle checkpoints within cells.

Pathways

CCNL2 is involved in significant cellular processes such as the cell cycle and mRNA processing pathways. A notable pathway includes the RNA splicing pathway where Cyclin L2 plays a role alongside proteins like cdk kinases which phosphorylate the C-terminal domain to facilitate splicing. Additionally it contributes to the regulation of the cell cycle coordinating with proteins such as cyclin-dependent kinases (CDK) to ensure proper cell cycle progression and division.

Cyclin L2 has associations with cancer and neurological disorders. Abnormal expression or malfunction of CCNL2 can contribute to tumorigenesis potentially through disrupted transcriptional and cell cycle control. In neurological disorders deviations from normal CCNL2 expression levels may impact neuron function and communication. Connections exist between CCNL2 and other proteins implicated in these conditions such as cyclin-dependent kinases which have roles in maintaining cellular homeostasis under normal and disease states.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com